Medtronic’s TYRX Warned Over CAPA, Change Control

The GMP Letter
A A
TYRX, a Medtronic subsidiary and developer of absorbable antibacterial envelopes, received an FDA warning letter for issues with CAPA investigations and change controls.

To View This Article:

Login

Subscribe To The GMP Letter